Trials / Conditions / Plasmodium Falciparum Infection

Plasmodium Falciparum Infection

23 registered clinical trials studyying Plasmodium Falciparum Infection.

Status	Trial	Sponsor	Phase
Completed	Pharmacokinetic Study of IV Artesunate to Treat Children With Severe Malaria NCT05750459	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 4
Completed	L9LS MAb in Malian Adults NCT05816330	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
Completed	Comparative Study of Thrombocytopenia in Plasmodium Vivax and Falciparum Malaria NCT07122232	Rafiullah Hotak	—
Completed	Anti-malaria MAb in Kenyan Children NCT05400655	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
Completed	Anti-malaria MAb in Malian Children NCT05304611	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
Unknown	Reducing Malaria Transmission in Forest-going Mobile and Migrant Populations in Myanmar NCT05025761	Macfarlane Burnet Institute for Medical Research and Public Health Ltd	N/A
Completed	Safety and Efficacy of CIS43LS Anti-malaria mAb in Mali NCT04329104	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
Completed	rCSP/AP10-602 [GLA-LSQ] Vaccine Trial NCT03589794	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
Completed	Study to Investigate the Clinical and Parasiticidal Activity and Pharmacokinetics of Different Doses of Artefe NCT03660839	Sanofi	Phase 2
Completed	Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of Three or Five Administrations of GAP3K NCT03168854	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
Completed	A Systems Biology Approach to Malaria Immunity NCT03014258	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
Completed	Safety and Efficacy of Sanaria's PfSPZ-CVac in Malian Adults NCT02996695	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
Completed	PfSPZ Challenge in Healthy Malaria-Naïve Adults in the United States NCT02773979	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
Completed	PfSPZ Challenge in Non-immune Adults in Baltimore, USA NCT02780154	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
Completed	Safety and Immunogenicity of Sanaria's Irradiated Sporozoite Vaccine (PfSPZ Vaccine) in Malaria-Experienced Ad NCT02663700	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
Terminated	To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine and NCT02497612	Sanofi	Phase 2
Completed	Efficacy and Safety of Dihydroartemisinin-piperaquine (DHP) for the Treatment of Uncomplicated Malaria NCT02353494	Menzies School of Health Research	—
Completed	Optimising Operational Use of Artemether-lumefantrine Comparing 3 Day Versus 5 Day NCT02020330	University of Oxford	Phase 3
Terminated	Dose Ranging Study of Ferroquine With Artesunate in African Adults and Children With Uncomplicated Plasmodium NCT00988507	Sanofi	Phase 2
Completed	Effect of Liver and Blood-stage Treatment on Subsequent Plasmodium Reinfection and Morbidity NCT02143934	Papua New Guinea Institute of Medical Research	Phase 4
Completed	Malaria Challenge With NF54 Strain NCT00744133	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
Completed	Chloroquine Alone or in Combination for Malaria in Children in Malawi NCT00379821	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3
Completed	Adenovirus Vaccine for Malaria NCT00371189	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1